CaixaBank, S.A. (BME:CABK)

Verve Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-	5,787	4,816	3,129	5,226	1,381
Depreciation & Amortization	-	558	573	555	546	415
Other Amortization	-	220	201	175	149	125
Change in Trading Asset Securities	-	104	910	4,820	14,196	-475
Change in Other Net Operating Assets	-	9,630	7,394	-88,252	20,978	33,744
Other Operating Activities	-	547	1,850	-302	-2,467	2,372
Operating Cash Flow	-	16,846	15,744	-79,875	38,628	37,562
Operating Cash Flow Growth	-	7.00%	-	-	2.84%	-
Capital Expenditures	-	-317	-412	-440	-358	-403
Sale of Property, Plant and Equipment	-	83	134	138	311	228
Cash Acquisitions	-	-	-	-250	-	-
Investment in Securities	-	89	80	152	159	644
Divestitures	-	-	-	-	277	-
Purchase / Sale of Intangibles	-	-433	-373	-475	-319	-287
Other Investing Activities	-	426	774	1,039	13,818	302
Investing Cash Flow	-	-152	203	164	13,888	484
Long-Term Debt Issued	-	1,750	2,318	750	1,750	746
Long-Term Debt Repaid	-	-2,000	-1,500	-1,760	-665	-
Net Debt Issued (Repaid)	-	-250	818	-1,010	1,085	746
Issuance of Common Stock	-	23	19	15	8	6
Repurchase of Common Stock	-	-1,292	-513	-1,818	-15	-8
Common Dividends Paid	-	-3,947	-1,728	-1,178	-216	-418
Other Financing Activities	-	714	2,797	7	-774	-1,866
Financing Cash Flow	-	-4,752	1,393	-3,984	88	-1,540
Foreign Exchange Rate Adjustments	-	1	-1	1	1	-5
Net Cash Flow	-	11,943	17,339	-83,694	52,605	36,501
Free Cash Flow	-	16,529	15,332	-80,315	38,270	37,159
Free Cash Flow Growth	-	7.81%	-	-	2.99%	-
Free Cash Flow Margin	-	111.53%	118.62%	-788.72%	409.52%	480.22%
Free Cash Flow Per Share	-	2.28	2.05	-10.27	5.05	6.22
Cash Interest Paid	-	9,591	7,397	1,281	2,637	2,123
Cash Income Tax Paid	-	1,447	59	395	851	150

Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Banks template. Financial Sources.